MedMira Inc. (TSXV: MIR)

Market Cap	61.27M
Revenue (ttm)	412.57K
Net Income (ttm)	-3.33M
Shares Out	720.81M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,040
Open	0.0850
Previous Close	0.0750
Day's Range	0.0850 - 0.0850
52-Week Range	0.0700 - 0.1200
Beta	10.66
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About MedMira

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screenin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 52
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MIR

Financial Performance

In 2024, MedMira's revenue was 412,568, a decrease of -4.61% compared to the previous year's 432,529. Losses were -3.33 million, 24.3% more than in 2023.